2013-03-28T16:59:21-05:00 2012-06-30 860683059 BEACHFLEISCHMAN PC PO BOX 64130 TUCSON AZ 857284130 990 2011-07-01 201991334 CRITICAL PATH INSTITUTE CRIT 5205473440 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 JOYCE ROGERS 5205473440 2013-03-22 1 KAREN K MCCLOSKEY CPA P00099644 5203214600 2011 2016-02-25 16:41:14Z CAROLYN COMPTON MD PHD 1730 EAST RIVER ROAD NO 200 TUCSON AZ 857185898 10603212 0 X WWW.C-PATH.ORG X 2004 AZ FOSTER AND CONDUCT RESEARCH AND EDUCATIONAL PROGRAMS THAT WILL LEAD TO SAFER MEDICAL PRODUCTS. 15 13 73 0 0 0 7857830 7998909 1692884 2560898 16840 21292 47398 20745 9614952 10601844 320561 463426 0 0 5312512 5755668 0 0 161088 3531836 4187345 9164909 10406439 450043 195405 8209894 9068693 4440417 5103811 3769477 3964882 X TO IMPROVE HUMAN HEALTH AND WELL-BEING BY DEVELOPING NEW TECHNOLOGIES AND METHODS TO ACCELERATE THE DEVELOPMENT AND REVIEW OF MEDICAL PRODUCTS. 0 0 8066407 463429 2581643 THE CRITICAL PATH INSTITUTE (C-PATH) IS AN INDEPENDENT, NON-PROFIT ORGANIZATION UNIQUELY DEDICATED TO IMPLEMENTING THE FDA'S CRITICAL PATH INITIATIVE BY CREATING COLLABORATIONS AMONG REGULATORS (SCIENTISTS FROM THE FDA) AND THE REGULATED (MEDICAL PRODUCT INDUSTRY) THAT RESULT IN ACCELERATED DEVELOPMENT OF SAFE, NEW MEDICAL PRODUCTS. THE ACCOMPLISHMENTS FOR THIS FISCAL YEAR REPORT INCLUDE:THE COALITION AGAINST MAJOR DISEASES (CAMD) WAS CREATED TO DEVELOP TOOLS AND PROCESSES TO ACCELERATE PROGRESS IN THE PREVENTION, TREATMENT AND CURE OF MAJOR NEURODEGENERATIVE DISEASES, INITIALLY FOCUSING ON ALZHEIMER'S AND PARKINSON'S DISEASES. ACCOMPLISHMENTS INCLUDE: 1) ITS PUBLIC DATABASE OF ALZHEIMER'S DISEASE CLINICAL TRIALS CONTINUES TO GROW IN SIZE AND USE. DATA FROM TWENTY FOUR CLINICAL TRIALS OF MEMBER COMPANIES COMPRISING 6,500 PATIENTS HAVE BEEN REMAPPED INTO THE NEW DATA STANDARD. THE DATABASE IS BEING USED BY NEARLY 250 SCIENTISTS FROM AROUND THE WORLD. 2) USING THE DATA FROM THAT DATABASE, AND DATA FROM THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE STUDIES, AN ALZHEIMER'S DISEASE PROGRESSION MODEL HAS BEEN CREATED. THE MODEL, ALONG WITH A SIMULATION INFRASTRUCTURE, HAS BEEN SUBMITTED TO THE FDA FOR A FORMAL REGULATORY DECISION ON ITS FIT FOR PURPOSE IN DESIGNING CLINICAL TRIALS FOR ALZHEIMER'S DISEASE. 3) A SERIES OF CEREBRAL SPINAL FLUID (CSF) AND HIPPOCAMPAL IMAGING BIOMARKERS HAVE BEEN IDENTIFIED AS POTENTIALLY USEFUL IN IDENTIFYING EARLY SYMPTOMATIC PATIENTS WITH A HIGH LIKELIHOOD OF CONVERSION TO FULL DEMENTIA IN A SHORT PERIOD OF TIME FOR INCLUSION IN CLINICAL TRIALS. LOW HIPPOCAMPAL VOLUME HAS BEEN QUALIFIED BY THE EUROPEAN MEDICINES AGENCY (EMA) FOR USE IN ENRICHING ALZHEIMER'S DISEASE CLINICAL TRIALS. A RESEARCH PLAN FOR BOTH SETS OF BIOMARKERS HAS BEEN WRITTEN AND SUBMITTED TO THE FDA. CAMD MEMBERS HAVE MET WITH THE FDA AND RECEIVED FEEDBACK FROM THE FDA AND HAVE RESPONDED TO THEIR QUESTIONS. THE PLANS ARE BEING EXECUTED NOW. 4) A DRAFT OF THE CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC) STANDARDS FOR PARKINSON'S DISEASE HAS BEEN DEVELOPED AND PUBLISHED AND IS AVAILABLE FOR USE. 5) A BRIEFING PACKAGE FOR SPECT IMAGING OF DOPAMINE TRANSPORT ACTIVITY FOR USE AS A CLINICAL TRIAL ENRICHMENT CRITERIA FOR PARKINSON'S DISEASE HAS BEEN WRITTEN AND IS BEING REVIEWED IN PREPARATION FOR SUBMISSION TO THE FDA. 6) AN EFFORT HAS BEGUN TO DEVELOP AN IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT FOR EARLY STAGES OF ALZHEIMER'S DISEASE.THE PATIENT-REPORTED OUTCOMES CONSORTIUM (PRO) WAS CREATED TO IDENTIFY AND PRIORITIZE THE MEDICAL PRODUCT DEVELOPMENT AREAS WHERE PRO INSTRUMENTS ARE NEEDED, ESTABLISH QUALIFICATION DOSSIERS TO REGULATORY AGENCIES FOR QUALIFICATION OF PRO INSTRUMENTS FOR USE IN REGULATORY AND DEVELOPMENTAL DECISION MAKING. THE FOLLOWING WORKING GROUPS HAVE SUBMITTED SCOPING STAGE SUMMARY DOCUMENTS TO THE FDA: COGNITION, IRRITABLE BOWEL SYNDROME, ASTHMA, DEPRESSION, NON-SMALL CELL LUNG CANCER, RHEUMATOID ARTHRITIS, AND FUNCTIONAL DYSPEPSIA. ALL HAVE BEEN SUCCESSFULLY REVIEWED. ALL WORKING GROUPS EXCEPT FUNCTIONAL DYSPEPSIA ARE EXECUTING THEIR QUALITATIVE RESEARCH. THE FUNCTIONAL DYSPEPSIA WORKING GROUP IS IN THE FINAL STAGES OF EXECUTING THEIR CONTRACT WITH THE SELECTED CONTRACT RESEARCH ORGANIZATION (CRO). THE COGNITION WORKING GROUP IS REVIEWING THE RESULTS OF THE QUALITATIVE RESEARCH AND IS IN THE PROCESS OF CONTRACTING THE QUANTITATIVE ANALYSIS OF THE DRAFT INSTRUMENT. FULL PSYCHOMETRIC TESTING OF THE INSTRUMENT WILL FOLLOW THAT.THE PREDICTIVE SAFETY TESTING CONSORTIUM (PSTC) COMPILES, GENERATES, AND SUBMITS FOR REGULATORY REVIEW DATA ON NEW SAFETY BIOMARKERS TO BE USED IN DRUG DEVELOPMENT, THUS ADVANCING THE DRUG SAFETY ASSESSMENT PROCESS. THE HEPATOTOXICITY, NEPHROTOXICITY, AND SKELETAL MUSCLE WORKING GROUPS HAVE COMPLETED NEARLY 100 STUDIES AND LOADED THE DATA INTO THE DATABASE FOR ANALYSIS. ALL THREE WORKING GROUPS HAVE SUBMITTED A BRIEFING PACKAGE TO THE FDA FOR REVIEW. THESE THREE WORKING GROUPS HAVE EXECUTED THEIR RESEARCH PLANS AND ARE IN THE PROCESS OF WRITING THE BRIEFING PACKAGES FOR SUBMISSION TO THE FDA AND EMA. FURTHERMORE, TO BEGIN THE WORK OF TRANSLATING THE BIOMARKERS FOR USE ON HUMANS, A STUDY WAS CONDUCTED ON HEALTHY VOLUNTEERS TO DETERMINE THE NORMAL STANDARD LEVELS OF THE BIOMARKERS IN HEALTHY INDIVIDUALS. STUDIES TO MONITOR THE BIOMARKERS IN PATIENTS UNDERGOING POTENTIALLY TOXIC THERAPIES ARE IN PROGRESS IN CONJUNCTION WITH THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH. WORK IS ALSO UNDERWAY TO ASSESS THE VALUE OF PRECLINICAL BIOMARKERS TO DETECT DRUG INDUCED INJURY IN THE VASCULAR AND TESTICULAR SYSTEMS, AND DRUG INDUCED CARDIAC HYPERTROPHY.THE CRITICAL PATH TO TB REGIMENS (CPTR) IS A COLLABORATION WITH THE BILL AND MELINDA GATES FOUNDATION AND THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT. THE GOAL OF THIS COLLABORATION IS TO SIGNIFICANTLY SPEED DEVELOPMENT OF INNOVATIVE TREATMENTS FOR TUBERCULOSIS. THEY HAVE DEVELOPED AND RELEASED A DATA STANDARD FOR COLLECTING AND STORING CLINICAL TRIAL DATA. THE BIOMARKER AND CLINICAL ENDPOINT WORKING GROUP HAS WRITTEN A LETTER OF INTENT TO THE FDA ON THE VALUE OF LIQUID CULTURE AS A PROGNOSTIC BIOMARKER FOR DRUG EFFICACY AND HAVE RECEIVED GUIDANCE ON HOW TO PROCEED. WORK IS UNDERWAY TO QUALIFY A HOLLOW FIBER MODEL. THE PRECLINICAL AND CLINICAL SCIENCES WORKING GROUP HAS WRITTEN WHITE PAPERS EXPLAINING THE EVALUATION OF EXISTING MODELS TO DETERMINE THEIR LEVEL OF VALIDATION AND APPROPRIATENESS FOR USE IN TB DRUG DEVELOPMENT. A PARTNERSHIP WITH THE POLYCYSTIC KIDNEY DISEASE (PKD) FOUNDATION TO QUALIFY TOTAL KIDNEY VOLUME AS A PROGNOSTIC BIOMARKER FOR PKD HAS MADE SIGNIFICANT PROGRESS. A DATA STANDARD HAS BEEN DEVELOPED AND IS IN FINAL REVIEW. A DATABASE HAS BEEN CREATED FROM REGISTRY DATA FROM THREE ACADEMIC INSTITUTIONS AND TWO NIH STUDIES. IT CONTAINS LONGITUDINAL DATA FROM OVER 3000 PKD PATIENTS. THE DATA IS BEING ANALYZED NOW AND A FINAL BRIEFING PACKAGE IS BEING GENERATED FOR SUBMISSION TO THE FDA. TWO MEETINGS WITH THE FDA WERE HELD THIS YEAR WHERE THE PLANS WERE PRESENTED, QUESTIONS WERE ANSWERED, AND ADJUSTMENTS WERE MADE TO THE RESEARCH PLANS AS A RESULT.A NEW CONSORTIUM WAS LAUNCHED IN COLLABORATION WITH THE NATIONAL MULTIPLE SCLEROSIS (MS) SOCIETY TO DEVELOP DATA STANDARDS FOR MS, CREATE A DATABASE OF EXISTING CLINICAL TRIAL DATA, AND DEVELOP A NEW IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT FOR USE IN CLINICAL TRIALS THAT IS QUALIFIED BY THE FDA. 8066407 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 1 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 47 0 1 73 1 0 0 0 0 0 0 0 0 0 0 X 15 13 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 1 1 1 0 AZ X JOYCE ROGERS 5207772883 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 857185898 THORIR BJORNSEN MD 32.00 X 198613 0 16624 J LYLE BOOTMAN PHD 1.00 X 0 0 0 CRAIG BRATER 1.00 X 0 0 0 SAM BRODER 1.00 X 0 0 0 M WAINWRIGHT FISHBURN JR 1.00 X 0 0 0 JIM GREENWOOD 1.00 X 0 0 0 MIKE KASSER 1.00 X 0 0 0 SHAUN A KIRKPATRICK 1.00 X 0 0 0 JAMES T KOLBE 1.00 X 0 0 0 CINDY PARSEGHIAN 1.00 X 0 0 0 ALASTAIR JJ WOOD MD 1.00 X 0 0 0 PETER B CORR MD 1.00 X X 0 0 0 JEFFREY JACOB 1.00 X X 0 0 0 RAYMOND L WOOSLEY MD PHD 60.00 X X 372989 0 41011 CAROLYN COMPTON MD PHD 60.00 X X 0 0 0 JOSEPH R ASSENZO PHD 20.00 X X 52901 0 4260 CELINDA JOHNSON 50.00 X X 142041 0 18479 RICHARD T MYERS 50.00 X X 211810 0 28980 STEVEN BROADBENT MBA 50.00 X 152202 0 24108 JOYCE ROGERS CMA MBA 40.00 X 0 0 0 RALPH MARTEL PHD 40.00 X 176879 0 30171 MARIETTA ANTHONY PHD 40.00 X 148480 0 13649 MARC CANTILLON MD 40.00 X 210000 0 18735 ESLIE DENNIS MD 40.00 X 246025 0 30599 STEPHEN COONS PHD 40.00 X 170713 0 21082 2082653 0 247698 16 0 1 0 UNITED BIOSOURCE CORPORATION LOCKBOX 758641 BALTIMORE MD 21275 RESEARCH 439534 RTI HEALTH SOLUTIONS PO BOX 900002 RALEIGH NC 27675 RESEARCH 206423 EPHIBIAN 3180 N SWAN RD TUCSON AZ 85712 DATABASE DEVELOPMENT 145935 MARTHA A BRUMFIELD LLC 400 E 85TH STREET 170 NEW YORK NY 10028 CONTRACT CONSULTING 141690 HEALTH RESEARCH ASSOCIATES 6505 216TH STREET SW SUITE 105 MOUNTLAKE TERRACE WA 98043 RESEARCH 141191 10 2892775 5106134 1064 7998909 RESEARCH SUPPORT FEES 541700 2468297 2468297 REGISTRATION FEES 900099 92601 92601 2560898 22660 22660 1368 -1368 -1368 -1368 REIMBURSED EXPENSES 541700 20745 20745 20745 10601844 2581643 0 21292 463426 463426 1248266 701946 545295 1025 3555810 2568729 913096 73985 298761 207018 86354 5389 337325 242821 88472 6032 315506 214658 95863 4985 92277 87256 4773 248 90581 52551 36810 1220 109805 74707 33363 1735 2155722 2106121 8979 40622 7103 6308 214 581 260487 205261 51337 3889 210058 200679 8915 464 434176 214483 213457 6236 324109 286092 32195 5822 210124 198463 6307 5354 183518 149559 32305 1654 40524 27571 12313 640 MISCELLANEOUS 44598 41917 1968 713 DUES AND SUBSCRIPTIONS 24263 16841 6928 494 10406439 8066407 2178944 161088 293009 753417 3219837 3933771 319648 49318 517696 689104 25467 70002 910305 581933 460501 328372 3346595 3217568 27141 27141 8209894 9068693 476090 312161 3964327 4791650 4440417 5103811 X 3577745 3807584 191732 157298 3769477 3964882 8209894 9068693 195405 0 X 0 1 1 X 1 1 X 3711438 5016728 5617050 7857830 7998908 30201954 3711438 5016728 5617050 7857830 7998908 30201954 348593 29853361 73625 34114 30965 34431 22660 195795 17970 41243 30697 20745 110655 30508404 7055426 0.97850 0.96760 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: REIMBURSED EXPENSES RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 109805 109805 10296633 10406438 670322 167581 0 0 422883 467663 630748 670322 2191616 3287424 108811 108342 108886 109805 435844 105721 116916 157687 167581 547905 821858 136608 79425 57183 314384 195543 118841 459313 306965 152348 328372 10601844 10406439 195405 195405 10605362 2150 2150 10603212 -1368 -1368 10601844 10409957 2150 1368 3518 10406439 0 10406439 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. ACCORDINGLY, NO PROVISION FOR FEDERAL AND STATE INCOME TAXES IS MADE IN THE FINANCIAL STATEMENTS. INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME (UBTI). GAAP REQUIRES MANAGEMENT TO PERFORM AN EVALUATION OF ALL TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN THE COURSE OF PREPARING C-PATH'S TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS MEET A "MORE LIKELY THAN NOT" STANDARD OF BEING SUSTAINED UNDER EXAMINATION BY THE APPLICABLE TAXING AUTHORITIES. THIS EVALUATION IS REQUIRED TO BE PERFORMED FOR ALL OPEN TAX YEARS, AS DEFINED BY THE VARIOUS STATUTES OF LIMITATIONS, FOR FEDERAL AND STATE PURPOSES. C-PATH IS ONLY SUBJECT TO INCOME TAXES ON UBTI AS APPLICABLE. AS A RESULT, C-PATH IS REQUIRED TO FILE INFORMATIONAL RETURNS FOR FEDERAL AND STATE PURPOSES AND, IF IT HAS UBTI, FEDERAL AND STATE INCOME TAX RETURNS. WITH LIMITED EXCEPTIONS, C-PATH IS NO LONGER SUBJECT TO TAX EXAMINATION FOR ANY YEARS EARLIER THAN 2009 FOR FEDERAL AND 2008 FOR STATE. MANAGEMENT HAS PERFORMED ITS EVALUATION OF TAX POSITIONS TAKEN ON ALL OPEN TAX RETURNS AND HAS DETERMINED THAT THERE WERE NO POSITIONS TAKEN THAT DO NOT MEET THE "MORE LIKELY THAN NOT" STANDARD. PART XII, LINE 4B - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF ASSET -1,368. PART XIII, LINE 2D - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF ASSET 1,368. 1 UNIVERSIETY OF ARIZONA 888 N EUCLID AVE ROOM 150 TUCSON AZ 85719 742652689 PUBLIC UNIVERSITY 152424 ARIZONA CENTER FOR EDUCATION AND RESEARCH ON THERAPEUTICS PROJECT INSTITUTE ON SCIENCE FOR GLOBAL POLICY 3320 N CAMPBELL AVE SUITE 200 TUCSON AZ 85719 453998749 501(C)(3) 311002 RESEARCH INTO EMERGING SCIENCE AND TECHNOLOGY ISSUES 2 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: A SUBAWARD AGREEMENT IS ENTERED INTO WITH THE UNIVERSITY OF ARIZONA FOR THE ARIZONA CENTER FOR EDUCATION AND RESEARCH ON THERAPEUTICS PROJECT. CRITICAL PATH HAS ALSO ENTERED INTO A SUBAWARD AGREEMENT WITH THE INSTITUTE ON SCIENCE FOR GLOBAL POLICY (ISGP), AND REVIEWS PROGRESS DELIVERABLES AND COSTS FROM ISGP. THE ORGANIZATION THEN SUBMITS INVOICES TO THE GOVERNMENT AGENCIES WHO FUND THE WORK. SUBCONTRACTOR INVOICES ARE DETAILED AND SUPPLEMENTED BY REGULAR NARRATIVE PROGRESS REPORTS. THE CRITICAL PATH INSTITUTE IS IN REGULAR COMMUNICATION WITH ISGP ON PROGRESS OF DELIVERABLES AND COMMUNICATES PROGRESS TO GOVERNMENT AGENCIES. X X 1 1 X X X X X X 0 0 0 0 0 0 0 0 0 THORIR BJORNSEN MD 198613 0 0 0 0 0 15673 0 951 0 215237 0 0 0 RAYMOND L WOOSLEY MD PHD 372989 0 0 0 0 0 24663 0 16348 0 414000 0 0 0 CELINDA JOHNSON 142041 0 0 0 0 0 11318 0 7161 0 160520 0 0 0 RICHARD T MYERS 211810 0 0 0 0 0 16896 0 12084 0 240790 0 0 0 STEVEN BROADBENT MBA 152202 0 0 0 0 0 12247 0 11861 0 176310 0 0 0 RALPH MARTEL PHD 176879 0 0 0 0 0 14320 0 15851 0 207050 0 0 0 MARIETTA ANTHONY PHD 148480 0 0 0 0 0 11854 0 1795 0 162129 0 0 0 MARC CANTILLON MD 210000 0 0 0 0 0 16800 0 1935 0 228735 0 0 0 ESLIE DENNIS MD 246025 0 0 0 0 0 19154 0 11445 0 276624 0 0 0 STEPHEN COONS PHD 170713 0 0 0 0 0 13600 0 7482 0 191795 0 0 0 FORM 990, PART VI, SECTION A, LINE 8B THERE ARE NO COMMITTEES WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S ACCOUNTING SPECIALIST, TREASURER, COO, PRESIDENT/CEO, AND ANOTHER OUTSIDE CPA PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS AND DIRECTORS MUST FILL OUT CONFLICT OF INTEREST DISCLOSURES ANNUALLY. EMPLOYEES COMPLETE THE CONFLICT OF INTEREST FORM UPON HIRING AND UPDATE THE DOCUMENT AS NEEDED. EMPLOYEES ARE REMINDED ANNUALLY TO REVIEW THEIR STATUS. THESE DISCLOSURES ARE REVIEWED BY THE PRESIDENT/CEO. THE COO AND THE SECRETARY/TREASURER REVIEW THE PRESIDENT/CEO'S DISCLOSURES. FORM 990, PART VI, SECTION B, LINE 15 A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. EVERY FEW YEARS THE COMMITTEE SEEKS AN INDEPENDENT COMPENSATION CONSULTING ORGANIZATION. AFTER THE CONSULTING ORGANIZATION HAS BEEN RETAINED, THE COMPENSATION COMMITTEE RECEIVES THE CONSULTANT'S EXECUTIVE COMPENSATION REVIEWS AND RECOMMENDATIONS. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/ CEO. THE LAST INDEPENDENT COMPENSATION SURVEY WAS CONDUCTED FOR THE CEO IN AUGUST 2011. FORM 990, PART VI, SECTION C, LINE 19 ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. THE CRITICAL PATH FOUNDATION 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 85718 204780896 RAISING AND CONTRIBUTING FUNDS TO CRITICAL PATH INSTITUTE AZ 501(C)(3) 11 CRITICAL PATH INSTITUTE 1 CRITICAL PATH GLOBAL LTD 1730 EAST RIVER ROAD SUITE 200 TUCSON AZ 85718 FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY UK CRITICAL PATH INSTITUTE 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0